{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:52:14Z","timestamp":1775620334715,"version":"3.50.1"},"reference-count":38,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> The goal of the present cohort study was to review outcomes of patients exposed to interferon beta-1b during pregnancy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> Pregnancy cases with exposure to interferon beta-1b reported to Bayer\u2019s pharmacovigilance (PV) database from worldwide sources from January 1995 through February 2018 were retrieved for evaluation. Only cases where pregnancy outcomes were unknown at the time of reporting (i.e. prospective cases) were included in the analysis of this retrospective cohort study. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> As of February 2018, 2581 prospective pregnancies exposed to interferon beta-1b were retrieved from the database; 1348 pregnancies had documented outcomes. The majority of outcomes [1106 cases (82.0%)] were live births. Health status was known for 981 live births (no known health status for 125). Most of the prospective pregnancies with known outcomes corresponded to live births with no congenital anomalies [896 cases (91.3%)]. Spontaneous abortion occurred in 160 cases (11.9%). Congenital birth defects were observed in 14\/981 live births with known health status [1.4%, 95% confidence interval (CI) 0.78\u20132.38]. No consistent pattern in the type of birth defect was identified. Rates of both spontaneous abortion and birth defects were not higher than the general population. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p> These PV data, the largest sample of interferon beta-1b-exposed patients reported to date, suggest no increase in risk of spontaneous abortion or congenital anomalies in women exposed during pregnancy. <\/jats:p><\/jats:sec>","DOI":"10.1177\/1756286420910310","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T09:12:36Z","timestamp":1583745156000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4467-9011","authenticated-orcid":false,"given":"Kerstin","family":"Hellwig","sequence":"first","affiliation":[{"name":"Department of Neurology, St. Joseph and St. Elisabeth Hospital, Ruhr University, Bleichstrasse 15, Bochum, 44787, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Duarte Caron","sequence":"additional","affiliation":[{"name":"Bayer, Whippany, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Maria","family":"Wicklein","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aasia","family":"Bhatti","sequence":"additional","affiliation":[{"name":"Bayer, Whippany, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Adamo","sequence":"additional","affiliation":[{"name":"Bayer AG, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"bibr1-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1191\/1352458504ms1083oa"},{"key":"bibr2-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0496-6"},{"key":"bibr3-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517751049"},{"key":"bibr4-1756286420910310","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline: disease-modifying therapies for adults with multiple sclerosis. Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology, https:\/\/download.lww.com\/wolterskluwer_vitalstream_com\/PermaLink\/WNL\/A\/WNL_2018_04_19_RAEGRANT_NEUROLOGY2017835181R1_SDC3.pdf. (2018, accessed 7 December 2018)."},{"key":"bibr5-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2012.04.024"},{"key":"bibr6-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003078"},{"key":"bibr7-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306222"},{"key":"bibr8-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61194-5"},{"key":"bibr9-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70237-6"},{"key":"bibr10-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000237641.33768.8d"},{"key":"bibr11-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.4.655"},{"key":"bibr12-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.7.1277"},{"key":"bibr13-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10039-9"},{"key":"bibr14-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004536"},{"key":"bibr15-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-308113"},{"key":"bibr16-1756286420910310","unstructured":"European Medicines Agency. Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data, https:\/\/www.ema.europa.eu\/documents\/regulatory-procedural-guideline\/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data_en.pdf. (accessed 15 January 2019)."},{"key":"bibr17-1756286420910310","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427040-00001"},{"key":"bibr18-1756286420910310","first-page":"1243","volume":"72","author":"Griebel CP","year":"2005","journal-title":"Am Fam Physician"},{"key":"bibr19-1756286420910310","unstructured":"EUROCAT. Prevalence tables, http:\/\/www.eurocat-network.eu\/accessprevalencedata\/prevalencetables. (accessed 7 December 2018)."},{"key":"bibr20-1756286420910310","unstructured":"US Centers for Disease Control. Update on overall prevalence of major birth defects - Atlanta, Georgia, 1978\u20132005, https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5701a2.htm. (accessed 7 December 2018)."},{"key":"bibr21-1756286420910310","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. FDA guidance for industry: postapproval pregnancy safety studies, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/postapproval-pregnancy-safety-studies-guidance-industry (accessed 25 February 2020)."},{"key":"bibr22-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04411-6"},{"key":"bibr23-1756286420910310","doi-asserted-by":"publisher","DOI":"10.25011\/cim.v33i6.14585"},{"key":"bibr24-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181fd62bb"},{"key":"bibr25-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516634872"},{"key":"bibr26-1756286420910310","volume-title":"Poster presented at the Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis","author":"Hellwig K"},{"key":"bibr27-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006384"},{"key":"bibr28-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390501"},{"key":"bibr29-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513507816"},{"key":"bibr30-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306054"},{"key":"bibr31-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-018-0110-3"},{"key":"bibr32-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.53"},{"key":"bibr33-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1159\/000242165"},{"key":"bibr34-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.6.1232"},{"key":"bibr35-1756286420910310","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932010-00002"},{"key":"bibr36-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1087105"},{"key":"bibr37-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418804760"},{"key":"bibr38-1756286420910310","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510394610"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756286420910310","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756286420910310","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756286420910310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T16:27:04Z","timestamp":1740932824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756286420910310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":38,"alternative-id":["10.1177\/1756286420910310"],"URL":"https:\/\/doi.org\/10.1177\/1756286420910310","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"1756286420910310"}}